Sutro Biopharma Inc
NASDAQ:STRO
Sutro Biopharma Inc
Cash from Financing Activities
Sutro Biopharma Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sutro Biopharma Inc
NASDAQ:STRO
|
Cash from Financing Activities
$137.6m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Sutro Biopharma Inc's Cash from Financing Activities?
Cash from Financing Activities
137.6m
USD
Based on the financial report for Dec 31, 2023, Sutro Biopharma Inc's Cash from Financing Activities amounts to 137.6m USD.
What is Sutro Biopharma Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-4%
Over the last year, the Cash from Financing Activities growth was 185%. The average annual Cash from Financing Activities growth rates for Sutro Biopharma Inc have been -20% over the past three years , -4% over the past five years .